Glenmark Pharmaceuticals Valuation Shifts to Very Attractive Amid Strong Market Performance

Valuation Metrics Reflect Enhanced Price Attractiveness

Recent data reveals Glenmark Pharma’s price-to-earnings (P/E) ratio stands at 21.26, a level that has contributed to its upgraded valuation grade to “very attractive.” This compares favourably against several peers in the sector, including Zydus Lifesciences with a P/E of 23.16 (attractive), and Dr Reddy’s Laboratories at 31.09 (fair). Notably, Laurus Labs and Mankind Pharma trade at significantly higher P/E multiples of 98.29 and 48.57 respectively, underscoring Glenmark’s relative valuation appeal.

The price-to-book value (P/BV) ratio of 6.27, while elevated, remains justified by Glenmark’s robust return on capital employed (ROCE) of 40.27% and return on equity (ROE) of 26.86%. These profitability metrics highlight efficient capital utilisation and strong shareholder returns, supporting the premium valuation.

Enterprise Value Multiples and Growth Prospects

Examining enterprise value (EV) multiples, Glenmark’s EV to EBIT ratio is 15.63 and EV to EBITDA is 13.62, both indicative of a balanced valuation relative to earnings before interest and taxes. The EV to capital employed ratio of 6.58 and EV to sales of 3.68 further reinforce the company’s operational efficiency and market positioning.

Perhaps most striking is Glenmark’s PEG ratio of 0.12, signalling that the stock is undervalued relative to its earnings growth potential. This low PEG contrasts sharply with peers such as Zydus Lifesciences (4.57) and Mankind Pharma (3.62), suggesting Glenmark offers superior growth-adjusted valuation.

Stock Performance Outpaces Benchmarks

Glenmark’s stock price currently trades at ₹2,336.30, up from a previous close of ₹2,309.90, with a 52-week high of ₹2,536.85 and a low of ₹1,794.00. Despite a slight pullback over the past week (-4.33%) and month (-5.19%), the stock has delivered impressive returns over longer horizons. Year-to-date, Glenmark has gained 14.76%, outperforming the Sensex which is down 15.62%. Over one year, the stock’s return of 19.28% contrasts with the Sensex’s negative 11.20%, while over three and five years, Glenmark has surged 173.32% and 355.42% respectively, dwarfing the Sensex’s 9.24% and 22.37% gains.

Mojo Score and Rating Update

MarketsMOJO’s proprietary scoring system currently assigns Glenmark a Mojo Score of 65.0, reflecting a Hold rating. This represents a downgrade from a previous Buy rating as of 28 September 2026. The adjustment aligns with the stock’s recent price appreciation and valuation shift, signalling a more cautious stance despite the company’s strong fundamentals. Glenmark remains classified as a mid-cap stock within the Pharmaceuticals & Biotechnology sector, a segment characterised by innovation and steady growth prospects.

Comparative Valuation Within the Sector

When benchmarked against peers, Glenmark’s valuation stands out for its combination of reasonable multiples and strong profitability. Lupin, another notable peer, is rated “very attractive” with a P/E of 15.57 and EV to EBITDA of 9.45, but Glenmark’s superior ROCE and ROE metrics provide a compelling counterpoint. Conversely, companies such as Laurus Labs and Abbott India are deemed “very expensive,” trading at P/E multiples of 98.29 and 35.24 respectively, which may deter value-conscious investors.

Biocon and Alkem Laboratories, rated “attractive,” trade at higher P/E ratios of 69.01 and 27.46, with elevated EV to EBITDA multiples, indicating that Glenmark’s valuation is comparatively more appealing given its growth and profitability profile.

Dividend Yield and Shareholder Returns

Glenmark’s dividend yield remains modest at 0.21%, reflecting the company’s focus on reinvesting earnings to fuel growth and innovation. This is consistent with sector norms where capital allocation often prioritises research and development over immediate shareholder payouts. Investors seeking capital appreciation may find this approach favourable, especially given the company’s strong return metrics and valuation attractiveness.

Outlook and Investment Considerations

Glenmark Pharmaceuticals’ transition to a very attractive valuation grade is underpinned by a combination of solid earnings growth, efficient capital deployment, and a valuation that remains reasonable relative to peers. The company’s PEG ratio of 0.12 is particularly noteworthy, signalling that the stock is undervalued on a growth-adjusted basis. This metric is a critical consideration for investors seeking exposure to the Pharmaceuticals & Biotechnology sector, which is often characterised by rapid innovation cycles and evolving regulatory landscapes.

However, the recent downgrade from Buy to Hold by MarketsMOJO suggests that investors should monitor the stock’s price action and sector developments closely. The stock’s recent short-term underperformance relative to the Sensex, coupled with a high P/BV ratio, warrants a balanced approach. Investors may consider accumulating on dips while keeping an eye on broader market trends and company-specific catalysts such as new drug approvals or pipeline progress.

Overall, Glenmark’s strong fundamentals and improved valuation metrics position it well for medium to long-term investors seeking exposure to a mid-cap pharmaceutical player with growth potential and reasonable valuation.

Historical Performance Versus Sensex

Over the past decade, Glenmark has delivered a total return of 153.88%, closely tracking the Sensex’s 158.06%. However, the company’s outperformance over shorter and medium-term periods is striking. Over five years, Glenmark’s return of 355.42% vastly exceeds the Sensex’s 22.37%, while over three years, the stock’s 173.32% gain dwarfs the benchmark’s 9.24%. This performance underscores Glenmark’s ability to generate shareholder value beyond market averages, reinforcing the rationale behind its upgraded valuation status.

Conclusion

Glenmark Pharmaceuticals Ltd. has demonstrated a significant improvement in valuation attractiveness, supported by strong profitability, efficient capital use, and a compelling growth outlook. While the recent rating adjustment to Hold advises caution, the stock’s favourable P/E, PEG, and EV multiples relative to peers make it a noteworthy contender in the Pharmaceuticals & Biotechnology sector. Investors should weigh the company’s robust fundamentals against market dynamics and sector-specific risks to make informed decisions.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →